Evidence map›Paper›PMID 42116756›Full record

ArticleAnnals of medicine2026

Comprehensive analysis suggests CRIF1 is a potential target in breast cancer associated with prognosis and immune infiltration.

Yongping Li, Jie Liu, Ming Zhong, Weiping Yu, Hongbo Zhu, Xueting Wang, Hao Yuan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yongping LiDepartment of Breast and Thyroid Surgery, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
Jie LiuDepartment of Breast and Thyroid Surgery, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
Ming ZhongDepartment of Breast and Thyroid Surgery, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
Weiping YuDepartment of Breast and Thyroid Surgery, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
Hongbo ZhuDepartment of Pathology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
Xueting WangDepartment of Operating Room, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
Hao YuanDepartment of Breast and Thyroid Surgery, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCRIF1 is a multifunctional factor that regulates cell biological processes such as the cell cycle, cell proliferation, and energy metabolism, and it is a new molecule that contributes to the poor prognosis of many malignancies. However, its involvement in breast cancer development is not fully known. MATERIALS AND

methodsTo investigate the relationship between CRIF1 expression, prognosis, and clinical characteristics using The Cancer Genome Atlas (TCGA-BRCA). The relationship between CRIF1 expression and the immunological microenvironment was investigated using CIBERSORT, ESTIMATE. Breast tissue and CRIF1 expression were validated by IHC. A tiny interfering plasmid was designed to transiently transfect breast cancer cell lines, and proliferation-related functional tests were carried out. The effect of sh CRIF1 on tumor formation was confirmed using a subcutaneous tumor experiment in naked mice.

resultsWe discovered that CRIF1 was highly elevated in breast cancer tissues and associated with a poor prognosis. CRIF1 stimulates breast cancer cell proliferation, migration, and invasion. Knockdown decreased PI3K/AKT/mTOR signaling, which boosted autophagy activity. Immune infiltration research revealed that patients with high CRIF1 expression had higher CD8

conclusionUpregulation of CRIF1 in breast cancer cells enhances malignant behavior, which may be mediated by PI3K/AKT/mTOR signaling and is linked to cellular autophagy.

Indexed as

Breast NeoplasmsAnimalsAutophagyBiomarkers, TumorCell Cycle ProteinsCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMicePhosphatidylinositol 3-KinasesPrognosisProto-Oncogene Proteins c-aktSignal TransductionBiomarkers, TumorCell Cycle ProteinsGADD45GIP1 protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinasesbiomarkerbreast cancerCRIF1immunotherapyprognosis

Identifiers

PMID42116756
PMCPMC13169454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.